A potent, small-molecule dual insulin-like growth factor-1 receptor (IGF-1R)/insulin receptor (IR) kinase inhibitor. Inhibits IGF-1R and IR kinases with IC50 values of 35 nM and 75 nM, respectively. Linsitinib selectively blocks the autophosphorylation of both human IGF-1R and IR, inhibits the proliferation of a variety of tumor cell lines in vitro, and displays robust in vivo anti-tumor efficacy in an IGF-1R-driven xenograft model when administered orally. MW: 421.49. Purity ≥99% by HPLC
Size
25 mg
Concentration
n/a
Applications
n/a
Other Names
(1S,3S)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; OSI-906; OSI 906AA